• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Intraday Session

    9/23/22 2:44:36 PM ET
    $ABVC
    $AORT
    $ATHX
    $CASI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $ABVC alert in real time by email

    Gainers

    • Kiromic BioPharma (NASDAQ:KRBP) stock rose 71.7% to $0.44 during Friday's regular session. As of 13:30 EST, Kiromic BioPharma's stock is trading at a volume of 20.8 million, which is 3303.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $6.9 million.
    • Athersys (NASDAQ:ATHX) shares increased by 53.41% to $1.79. Trading volume for Athersys's stock is 34.4 million as of 13:30 EST. This is 4708.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $547.6 million.
    • Global Cord Blood (NYSE:CO) shares rose 33.78% to $2.97. As of 13:30 EST, this security is trading at a volume of 9.0 million shares, making up 6541.3% of its average full-day volume over the last 100 days. The company's market cap stands at $397.7 million.
    • ABVC BioPharma (NASDAQ:ABVC) shares increased by 16.58% to $0.94. As of 13:30 EST, ABVC BioPharma's stock is trading at a volume of 79.7K, which is 67.8% of its average full-day volume over the last 100 days. The company's market cap stands at $30.8 million.
    • Concord Medical Services (NYSE:CCM) stock increased by 16.04% to $1.88. The market value of their outstanding shares is at $81.6 million.
    • Sonendo (NYSE:SONX) shares increased by 14.64% to $1.04. As of 13:30 EST, this security is trading at a volume of 15.1 million shares, making up 12793.6% of its average full-day volume over the last 100 days. The company's market cap stands at $27.6 million.

    Losers

    • Artivion (NYSE:AORT) stock decreased by 29.4% to $13.06 during Friday's regular session. Trading volume for this security as of 13:30 EST is 1.0 million, which is 505.5% of its average full-day volume over the last 100 days. The company's market cap stands at $526.7 million.
    • Cassava Sciences (NASDAQ:SAVA) stock declined by 20.57% to $40.56. Trading volume for Cassava Sciences's stock is 11.1 million as of 13:30 EST. This is 361.2% of its average full-day volume over the last 100 days. The company's market cap stands at $1.6 billion.
    • RVL Pharmaceuticals (NASDAQ:RVLP) stock decreased by 20.31% to $2.06. The current volume of 312.5K shares is 179.9% of RVL Pharmaceuticals's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $204.6 million.
    • CASI Pharmaceuticals (NASDAQ:CASI) shares declined by 19.29% to $2.72. Trading volume for this security as of 13:30 EST is 253.6K, which is 120.9% of its average full-day volume over the last 100 days. The company's market cap stands at $37.0 million.
    • Minerva Surgical (NASDAQ:UTRS) stock fell 17.53% to $0.73. The market value of their outstanding shares is at $20.9 million.
    • RenovoRx (NASDAQ:RNXT) shares fell 17.41% to $1.97. As of 13:30 EST, this security is trading at a volume of 50.6K shares, making up 290.4% of its average full-day volume over the last 100 days. The company's market cap stands at $17.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ABVC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABVC
    $AORT
    $ATHX
    $CASI

    CompanyDatePrice TargetRatingAnalyst
    Artivion Inc.
    $AORT
    8/13/2025$38.79Buy → Neutral
    Ladenburg Thalmann
    Artivion Inc.
    $AORT
    6/17/2025$35.00Buy
    Canaccord Genuity
    Cassava Sciences Inc.
    $SAVA
    11/26/2024Buy → Neutral
    H.C. Wainwright
    Artivion Inc.
    $AORT
    10/23/2024$33.00Mkt Outperform
    JMP Securities
    Cassava Sciences Inc.
    $SAVA
    10/8/2024$116.00Neutral → Buy
    H.C. Wainwright
    Cassava Sciences Inc.
    $SAVA
    7/1/2024Buy → Neutral
    H.C. Wainwright
    Sonendo Inc.
    $SONX
    3/12/2024Buy → Hold
    Stifel
    Cassava Sciences Inc.
    $SAVA
    11/16/2022$44.00Buy → Neutral
    B. Riley Securities
    More analyst ratings

    $ABVC
    $AORT
    $ATHX
    $CASI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    VP, Chief Accounting Officer Horton Amy sold $34,036 worth of shares (901 units at $37.78) and was granted 7,475 shares, increasing direct ownership by 5% to 139,088 units (SEC Form 4)

    4 - ARTIVION, INC. (0000784199) (Issuer)

    3/4/26 6:54:39 PM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    SVP, General Counsel Holloway Jean F was granted 27,795 shares and sold $485,728 worth of shares (12,805 units at $37.93), increasing direct ownership by 9% to 185,095 units (SEC Form 4)

    4 - ARTIVION, INC. (0000784199) (Issuer)

    3/4/26 6:53:04 PM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    SVP, Clinical & MD Affair Stanton Marshall S. was granted 21,838 shares and sold $81,180 worth of shares (2,149 units at $37.78), increasing direct ownership by 49% to 60,097 units (SEC Form 4)

    4 - ARTIVION, INC. (0000784199) (Issuer)

    3/4/26 6:51:03 PM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    $ABVC
    $AORT
    $ATHX
    $CASI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    May 23, 2023 - FDA Roundup: May 23, 2023

    For Immediate Release: May 23, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Monday, the FDA and the Veterans Health Administration announced a new collaboration to jointly develop emergency preparedness and response tools and protocols intended to help increase medical product manufacturing capacity and flexibility, and improve resilie

    5/23/23 4:06:19 PM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    $ABVC
    $AORT
    $ATHX
    $CASI
    SEC Filings

    View All

    SEC Form DEF 14A filed by ABVC BioPharma Inc.

    DEF 14A - ABVC BIOPHARMA, INC. (0001173313) (Filer)

    3/5/26 4:29:58 PM ET
    $ABVC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Artivion Inc.

    144 - ARTIVION, INC. (0000784199) (Subject)

    3/3/26 4:42:40 PM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form 10-Q/A filed by ABVC BioPharma Inc.

    10-Q/A - ABVC BIOPHARMA, INC. (0001173313) (Filer)

    3/3/26 4:19:07 PM ET
    $ABVC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $AORT
    $ATHX
    $CASI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Artivion downgraded by Ladenburg Thalmann with a new price target

    Ladenburg Thalmann downgraded Artivion from Buy to Neutral and set a new price target of $38.80

    8/13/25 8:00:59 AM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    Canaccord Genuity initiated coverage on Artivion with a new price target

    Canaccord Genuity initiated coverage of Artivion with a rating of Buy and set a new price target of $35.00

    6/17/25 7:48:51 AM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    Cassava Sciences downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Cassava Sciences from Buy to Neutral

    11/26/24 7:44:43 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $AORT
    $ATHX
    $CASI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $ABVC
    $AORT
    $ATHX
    $CASI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Artivion to Participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference

    ATLANTA, March 3, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate virtually at the upcoming Oppenheimer 36th Annual Healthcare MedTech & Services Conference. The Company's virtual fireside chat is scheduled to begin at 9:20 a.m. ET on Tuesday, March 17, 2026. A live webcast can be accessed through Artivion's website, www.artivion.com, on the Investors page. An archived copy of the webcast will be available for 90 days on the same website.About Artivion, Inc.Headqua

    3/3/26 4:10:00 PM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum

    Over the past year, RenovoRx has Tripled Commercially Active U.S. Cancer Centers and Centers Requesting Access to RenovoCath, its FDA-Cleared Device Over 700 RenovoCath Procedures Successfully Completed Since FDA Clearance in 2014 Company Appoints Ramtin Agah, MD to the Additional Position of Executive Chairman to Support Continued Clinical Adoption and Commercial Growth MOUNTAIN VIEW, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced continued commercial progress, with

    2/27/26 8:30:00 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Radiology Annual Scientific Meeting

    MOUNTAIN VIEW, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that a clinical data abstract submission by cancer experts at Moffitt Cancer Center to the 2026 Society of Interventional Radiology (SIR) Annual Scientific Meeting has been accepted. The meeting will be held April 11-15, 2026, in Toronto, Ontario. The abstract, titled "What PET/CT Reveals After Transarterial Microperfusion for Pancreatic Cancer," was submitted by a multidisciplinary team of cancer experts, i

    2/26/26 8:30:00 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Agah Ramtin bought $9,975 worth of shares (10,000 units at $1.00), increasing direct ownership by 1% to 798,460 units (SEC Form 4)

    4 - RenovoRx, Inc. (0001574094) (Issuer)

    1/22/26 7:00:18 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Agah Ramtin bought $8,424 worth of shares (9,795 units at $0.86), increasing direct ownership by 1% to 788,460 units (SEC Form 4)

    4 - RenovoRx, Inc. (0001574094) (Issuer)

    1/5/26 7:00:02 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Agah Ramtin bought $169 worth of shares (205 units at $0.83), increasing direct ownership by 0.03% to 778,665 units (SEC Form 4)

    4 - RenovoRx, Inc. (0001574094) (Issuer)

    1/2/26 5:00:20 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $AORT
    $ATHX
    $CASI
    Leadership Updates

    Live Leadership Updates

    View All

    RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum

    Over the past year, RenovoRx has Tripled Commercially Active U.S. Cancer Centers and Centers Requesting Access to RenovoCath, its FDA-Cleared Device Over 700 RenovoCath Procedures Successfully Completed Since FDA Clearance in 2014 Company Appoints Ramtin Agah, MD to the Additional Position of Executive Chairman to Support Continued Clinical Adoption and Commercial Growth MOUNTAIN VIEW, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced continued commercial progress, with

    2/27/26 8:30:00 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer

    MOUNTAIN VIEW, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, is pleased to announce the appointment of Mark Voll as the Company's Chief Financial Officer, effective February 1, 2026. Mr. Voll brings more than three decades of financial leadership experience to RenovoRx, with a strong track record for guiding high-growth public companies through periods of commercial buildout and strategic development. He has served as Chief Financial Officer for multiple publicly traded technology co

    2/5/26 8:30:00 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cassava Reports Q3 2025 Financials Results and Provides Business Update

    Simufilam advancing towards a clinical study expected to begin in H1 2026 for the potential treatment of TSC-related epilepsyFurther fortified our strategic capabilities with the appointment of Dawn C. Bir to the Board of Directors$106.1 million in cash and cash equivalents at September 30, 2025. Expected to support operations into 2027 AUSTIN, Texas, Nov. 12, 2025 (GLOBE NEWSWIRE) -- – Cassava Sciences, Inc. (NASDAQ:SAVA, "Cassava", the "Company")), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today reported financial results for the third quarter ende

    11/12/25 8:00:00 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $AORT
    $ATHX
    $CASI
    Financials

    Live finance-specific insights

    View All

    Artivion Reports Fourth Quarter and Full Year 2025 Financial Results

    Fourth Quarter Highlights: GAAP revenue was $116.0 million in the fourth quarter of 2025 versus $97.3 million in the fourth quarter of 2024. For the full year, GAAP revenue was $441.3 million versus $388.5 million for the full year of 2024. GAAP net income was $2.4 million, or $0.05 per fully diluted share, in the fourth quarter of 2025, versus a net loss of $(16.5) million, or $(0.39) per fully diluted share in the fourth quarter of 2024. For the full year 2025, GAAP net income was $9.8 million, versus a net loss of $(13.4) million for the full year 2024.Adjusted revenue1 was $118.3 million in the fourth quarter of 2025, an increase of 18% on an adjusted constant currency basis compared to

    2/12/26 4:05:00 PM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    RenovoRx Reports Third Quarter 2025 Financial Results, Including Approximately $900,000 in Year-to-Date Revenue, and Provides Business Update

    September 30, 2025 Cash and Cash Equivalents at $10 million Revenue Expected to Grow in 2026 and Continue to Offset Cash Burn Management to Host Conference Call Today at 4:30 p.m. ET MOUNTAIN VIEW, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (NASDAQ:RNXT) ("RenovoRx" or the "Company"), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, today announced its financial results and provided a business update to shareholders for the third quarter ended September 30, 2025. "We continue to make strong progress both in our commercial and clinical activities," said Shaun Bagai, CEO of

    11/13/25 4:05:00 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Artivion Reports Third Quarter 2025 Financial Results

    Third Quarter Highlights: Achieved revenue of $113.4 million in the third quarter of 2025 versus $95.8 million in the third quarter of 2024, an increase of 18% on a GAAP basis and 16% on a non-GAAP constant currency basisNet income was $6.5 million, or $0.13 per fully diluted share, and non-GAAP net income was $7.9 million, or $0.16 per fully diluted share in the third quarter of 2025Adjusted EBITDA increased 39% to $24.6 million in the third quarter of 2025 compared to $17.7 million in the third quarter of 2024Enrolled first patient in ARTIZEN U.S. Investigational Device Exemption trial for ArcevoATLANTA, Nov. 6, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE:AORT), a leading cardiac and vascul

    11/6/25 4:05:00 PM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    $ABVC
    $AORT
    $ATHX
    $CASI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by ABVC BioPharma Inc.

    SC 13G/A - ABVC BIOPHARMA, INC. (0001173313) (Subject)

    11/14/24 7:33:18 PM ET
    $ABVC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sonendo Inc.

    SC 13G/A - Sonendo, Inc. (0001407973) (Subject)

    11/14/24 4:40:34 PM ET
    $SONX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Sonendo Inc.

    SC 13G - Sonendo, Inc. (0001407973) (Subject)

    11/14/24 1:23:43 PM ET
    $SONX
    Medical/Dental Instruments
    Health Care